- Home
- MBC vs IMTX Comparison
MBC vs IMTX Comparison
Compare MBC & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBC | IMTX |
|---|---|---|
| Founded | 1954 | N/A |
| Country | United States | Germany |
| Employees | N/A | 423 |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | MBC | IMTX |
|---|---|---|
| Price | $8.59 | $10.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $15.00 | ★ $19.25 |
| AVG Volume (30 Days) | ★ 2.8M | 341.7K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,734,700,000.00 | N/A |
| Revenue This Year | N/A | $1.92 |
| Revenue Next Year | $14.45 | $15.88 |
| P/E Ratio | $42.74 | ★ N/A |
| Revenue Growth | ★ 1.27 | N/A |
| 52 Week Low | $8.73 | $3.30 |
| 52 Week High | $14.23 | $12.41 |
Technical Indicators
Market Signals| Indicator | MBC | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 21.69 | 51.47 |
| Support Level | N/A | $9.66 |
| Resistance Level | $13.56 | $10.64 |
| Average True Range (ATR) | 0.59 | 0.54 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 11.47 | 62.16 |
Price Performance
Historical ComparisonAbout MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.